CAR T-Cell Therapy

Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting.

The administration of axicabtagene ciloleucel in the second-line setting improved overall survival and progression-free survival vs standard-of-care treatment in patients with relapsed/refractory large B-cell lymphoma who are at least 65 years of age.

The utilization of remote patient monitoring within the first 30 days of outpatient CAR T-cell therapy can promote patient safety, reduce costs, and decrease hospitalization rates by allowing patients with hematologic malignancies to connect with a virtual care platform.

Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.

Shortages of several anticancer drugs continue to negatively impact clinicians’ ability to deliver the best possible care to patients.

Michael Hurwitz, MD, PhD, discusses the ongoing investigation into the use of CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Adnan F. Danish, MD, discusses findings from a study evaluating the prevalence of patients with high-risk non-Hodgkin lymphoma who were eligible for bridging radiation therapy prior to receiving CAR T-cell therapy, as well as the outcomes of these patients following CAR T-cell therapy.

The FDA has received reports of T-cell malignancies in patients who have been treated with CD19- or BCMA-directed autologous CAR T-cell immunotherapies.

Adrienne Phillips, MD, MPH, discusses the impact of CAR T-cell therapy on the treatment paradigm for patients with large B-cell lymphoma, highlighting key advancements in the decision-making process for CAR T-cell therapy selection.

A biologics license application seeking the approval of obecabtagene autoleucel for the treatment of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.

Michael Hurwitz, MD, PhD, discusses the feasibility of utilizing CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Lori A. Leslie, MD, discusses the benefits of implementing CAR T-cell therapy programs for patients with hematologic malignancies and highlights the successes with administering CAR T-cell therapy that JTCC has experienced.

Adrienne Phillips, MD, MPH, discusses the management of toxicities associated with CAR T-cell therapy across hematologic malignancies.

Md Kamrul Hasan, PhD, discusses the preclinical efficacy and safety of ROR1-specific CAR T-cells in a preclinical mouse model of chronic lymphocytic leukemia.

The FDA’s Oncologic Drugs Advisory Committee will meet to review data from the supplemental biologics license application seeking the approval of idecabtagene vicleucel for use in earlier lines of treatment for patients with triple-class exposed relapsed/refractory multiple myeloma.

The HER2-directed CAR-macrophage therapy CT-0508 displayed a tolerable safety profile and signs of antitumor activity in patients with a variety of solid tumors.

Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.

Mark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.

The FDA has granted priority review to the supplemental biologics license application seeking approval to expand the indication of lisocabtagene maraleucel to include patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a BTK inhibitor and a BCL-2 inhibitor.

Mark Leick, MD, discusses the varying role of CAR T-cell therapy across various hematologic malignancies, elaborating on the cause of its effectiveness in these disease spaces.

Mark Leick, MD, discusses how the emergence of CAR T-cell therapies have affected the treatment paradigms in various hematologic malignancies, expands on how persisting challenges with the use of this type of treatment are being addressed, and details research into the use of CAR T-cell therapy in patients with solid tumors.

The FDA has cleared the investigational new drug application for CHM 2101, a novel CDH17-targeted CAR T-cell therapy, for the treatment of patients with gastrointestinal cancers.

The Claudin-6–directed CAR T-cell therapy, BNT211, showed signs of clinical activity in patients with CLDN6-positive relapsed or refractory solid tumors.

Hemant S. Murthy, MD, discusses the evolving use of CAR T-cell therapy for elderly or frail patients with relapsed/refractory B-cell lymphomas.

Hemant S. Murthy, MD, emphasizes the importance of an accelerated manufacturing process for CAR T-cell therapy, discusses the use of CAR T-cell therapy in older and frail patients, and highlights toxicity management strategies that have implemented and are under evaluation for patients receiving CAR T-cell therapy.